Collectives

Unit Trust (UK UCITS compliant)

Legal & General Global Health & Pharmaceuticals Index Trust

R-Class GBP Accumulation

ISINGB0001955532

Price

Fund aim

The objective of the Fund is to track performance of the FTSE World Index - Health Care, the "Benchmark Index" on a net total return basis before fees and expenses are applied. Fund performance may differ from the Benchmark Index due to the deduction of fees and expenses and the impact of any tracking error factors.

Fund snapshot

  • What does it invest in? Invests in the shares of global companies engaged in healthcare, pharmaceutical and biotechnology activities, as represented by the Index.
  • How does it invest? Passively managed, aiming to replicate the performance of the Index.

Fund facts

Fund size£1,059.3m
Base currencyGBP
Fund launch date1 Nov 2000
DomicileUK
Share class launch1 Nov 2000
Historical yield0.9%
As at 31 Jan 2024

Benchmark

FTSE World - Health Care Index

Costs

Initial charge0.00%
Ongoing charges figure0.69%
Dilution adjustment0.16% - round trip

Performance

Performance for the R Acc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference.
Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past. The tables and charts above shows the fund's performance as the percentage loss or gain per year over the last 10 years.
Share class launch date:01 Nov 2000
Benchmark:FTSE World - Health Care Index
Share class launch date:01 Nov 2000
Benchmark:FTSE World - Health Care Index
    Share class launch date:01 Nov 2000
    Benchmark:FTSE World - Health Care Index

    Portfolio breakdown

    As at 31 Jan 2024

    Top 10 holdings43.2%
    Rest of portfolio56.8%
    No. of holdings in fund195
    No. of holdings in index194

    Top 10 holdings (%)

    Eli Lilly & Co7.5
    Unitedhealth Group6.4
    Johnson & Johnson5.2
    Novo Nordisk B4.9
    Merck & Co4.2
    Abbvie3.9
    Novartis2.9
    Thermo Fisher Scientific2.9
    Roche Holding2.8
    Abbott Laboratories2.7

    Sector (%)

    Health Care
    100.0
    Other
    0.0

    All data source LGIM unless otherwise stated. Totals may not sum due to rounding. In order to minimise transaction costs, the Fund will not always own all the assets that constitute the index and on occasion it will own assets that are not in the index. The figures shown for market capitalisation (the total share value of a company) may not be comparable between funds as they can be measured and classed in different ways.

    Fund managers

    LGIM Index Fund Management Team headshot

    LGIM Index Fund Management Team

    The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.

    Literature

    Prices

    Pricing information

    Price basisSingle swing
    Price time15:00 UK time
    CurrencyGBP
    Monthly price history
    Please note that a maximum of 10 years price history is available.

    Codes and dealing

    Codes

    ISINGB0001955532
    SEDOL0195553
    BloombergLEGGHPA
    MEXLGHPIA

    Dealing information

    Valuation frequencyDaily, 3pm (UK time)
    Dealing frequencyDaily
    Settlement periodT+4

    Country registration

    This share class is registered for sale in the following countries:

    United Kingdom